TABLE 16

Article	DAR	ADC Dose	Payload Dose	Dosing Schedule	Total Payload Dose
Isotype Control-LP4	3.9-4	3.64-3.72 mg/kg	80 ug/kg	QW x3	240 ug/kg
Anti-STEAP2 N297Q Ab-LP4	3.9-4	1.82-1.86 mg/kg	40 ug/kg	QW x1	40 ug/kg
Anti-STEAP2 N297Q Ab-LP4	3.9-4	1.82-1.86 mg/kg	40 ug/kg	QW x3	120 ug/kg
Anti-STEAP2 N297Q Ab-LP4	3.9-4	3.64-3.72 mg/kg	80 ug/kg	QW x3	240 ug/kg

Results and Conclusions:

[0750] The anti-tumor efficacy of a STEAP2 Tubulysin ADC in a STEAP2 positive PDX model was assessed relative to control ADC. CTG-2440 tumors treated with the control ADC grew to protocol size limits within 28 days. Growth of tumors treated with STEAP2 Tubulysin ADC at 3.72 mg/kg (3 weekly doses of 80 ug/kg payload) was inhibited for 60 days with no deleterious effect on body weight change. The anti-tumor efficacy was dose dependent. Complete tumor inhibition was observed with a total payload dose of 240 ug/kg, while tumor regression was induced with 120 ug/kg and 40 ug/kg total payload doses. Tumor volume data for CTG-2440 are shown in FIG. **16**.

Tabulated Data Summary for CTG-2440:

[0751]

Antibody (mg/kg)	Total Payload Dose	Final tumor volume (mm^3) at termination (mean ± SD)	Tumor growth (mm^3) from start of treatment (mean ± SD)
Isotype Control-LP4 (3.72 mg/kg, QW x3)	240 ug/kg	1556.0 ± 747.7	1355.3 ± 724.0
Anti-STEAP2 N297Q Ab-LP4 (1.86 mg/kg, QW x1)	40 ug/kg	179.9 ± 68.5	−20.0 ± 65.1
Anti-STEAP2 N297Q Ab-LP4 (1.86 mg/kg, QW x3)	120 ug/kg	73.5 ± 53.4	−129.3 ± 67.7
Anti-STEAP2 N297Q Ab-LP4 (3.72 mg/kg, QW x3)	240 ug/kg	6.0 ± 11.4	−196.5 ± 37.1

[0752] CTG-2441 tumors treated with the control ADC grew to protocol size limits within 30 days. Growth of tumors treated with STEAP2 Tubulysin ADC at 3.64 mg/kg (3 weekly doses of 80 ug/kg payload) was inhibited for 60 days with only moderate weight loss observed. The anti-tumor efficacy was dose dependent. Complete tumor inhibition was observed with a total payload dose of either 120 or 240 ug/kg. Tumor regression was induced following a single administration of 40 ug/kg total payload dose.

[0753] Tumor volume data for CTG-2441 are shown in FIG. **17**.

Tabulated Data Summary for CTG-2441:

[0754]

Antibody (mg/kg)	Total Payload Dose	Final tumor volume (mm^3) at termination (mean ± SD)	Tumor growth (mm^3) from start of treatment (mean ± SD)
Isotype Control-LP4 (3.64 mg/kg, QW x3)	240 ug/kg	977.3 ± 390.0	770.3 ± 365.8
Anti-STEAP2 N297Q Ab-LP4 (1.82 mg/kg, QW x1)	40 ug/kg	171.8 ± 176.1	−36.8 ± 167.0
Anti-STEAP2 N297Q Ab-LP4 (1.82 mg/kg, QW x3)	120 ug/kg	46.0 ± 15.1	−164.0 ± 57.3
Anti-STEAP2 N297Q Ab-LP4 (3.64 mg/kg, QW x3)	240 ug/kg	33.5 ± 13.6	−179.1 ± 51.3

[0755] PDX Model and STEAP2 Expression Information:

[0756] The prostate cancer models were derived from the bone metastases of patients with metastatic castrate resistant prostate cancer (mCRPC). STEAP2 expression was confirmed by RNA sequencing data and RNA in situ hybridization.

1.-64. (canceled)

65. A compound having the following formula



or a pharmaceutically acceptable salt thereof, wherein

BA is a binding agent;

L is a linker covalently bound to BA and to T;